<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005027</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067548</org_study_id>
    <secondary_id>U01CA062487</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2063</secondary_id>
    <secondary_id>NCI-T99-0113</secondary_id>
    <nct_id>NCT00005027</nct_id>
  </id_info>
  <brief_title>Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer</brief_title>
  <official_title>A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating&#xD;
      patients who have advanced kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with advanced renal cell carcinoma when treated&#xD;
           with rebeccamycin analogue.&#xD;
&#xD;
        -  Assess the quantitative and qualitative toxicities associated with this drug in this&#xD;
           patient population.&#xD;
&#xD;
      OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days.&#xD;
      Treatment continues every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>becatecarin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed locally advanced unresectable, locally&#xD;
             recurrent, or metastatic renal cell carcinoma not eligible for a higher priority trial&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Longest diameter at least 20 mm with conventional techniques or at least 10 mm&#xD;
                  with spiral CT scan&#xD;
&#xD;
          -  No nonmeasurable disease only including:&#xD;
&#xD;
               -  Bone lesions&#xD;
&#xD;
               -  Leptomeningeal disease&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
               -  Pleural/pericardial effusion&#xD;
&#xD;
               -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
               -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
               -  Cystic lesions&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  History of brain metastases that have been resected and/or irradiated with&#xD;
                  subsequent normal brain CT scan allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of any site&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to rebeccamycin analogue&#xD;
&#xD;
          -  No other concurrent uncontrolled illness (e.g., ongoing or active infection)&#xD;
&#xD;
          -  No concurrent psychiatric illness or social situation that would preclude study&#xD;
             compliance&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
          -  Recovered from toxic effects&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for renal cell&#xD;
             cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka N. Vaishampayan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ibrahim D, Hussain M, LoRusso P, et al.: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): preliminary results of a phase II trial. [Abstract] Proceedings of the American Society of Clinical Oncology A-2373, 2001.</citation>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>August 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2003</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

